Recent Finacing
Recent Raise
Somnus Therapeutics develops SKP-1041, a delayed‑release zaleplon for sleep‑maintenance insomnia, conducts Phase 2 clinical trials, and partners with SkyePharma for formulation and manufacturing.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors